Skip to main content

Table 2 Lung high-resolution computed tomography (HRCT) scores for ground glass appearance

From: Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

 

Cross-over from placebo group*

Olipudase alfa group**

Baseline n = 18

Olipudase alfa for 1 year n = 14

Baseline n = 18

Year 1 n = 18

Year 2 n = 16

Mean ± SD

0.53 ± 0.64

0.22 ± 0.35

0.65 ± 0.72

0.15 ± 0.29

0.13 ± 0.25

LS mean ± SE change from baseline

 

− 0.37 ± 0.08

 

− 0.45 ± 0.13

− 0.48 ± 0.07

  1. *Received olipudase alfa for 1 year
  2. **Original olipudase alfa group received olipudase alfa for 2 years
  3. LS least square, SE standard error of the mean
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172